These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

968 related items for PubMed ID: 24219037

  • 1. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
    Castrejón I, Gibson KA, Pincus T.
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
    [Abstract] [Full Text] [Related]

  • 2. Update on methotrexate as the anchor drug for rheumatoid arthritis.
    Pincus T, Gibson KA, Castrejón I.
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S9-19. PubMed ID: 24219036
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D.
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB, von Kempis J, Haile SR, Schiff MH.
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [Abstract] [Full Text] [Related]

  • 7. Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies.
    Jacobs JW.
    Rheumatology (Oxford); 2012 Jun; 51 Suppl 4():iv27-33. PubMed ID: 22685273
    [Abstract] [Full Text] [Related]

  • 8. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 9. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.
    Katchamart W, Trudeau J, Phumethum V, Bombardier C.
    Cochrane Database Syst Rev; 2010 Apr 14; 2010(4):CD008495. PubMed ID: 20393970
    [Abstract] [Full Text] [Related]

  • 10. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.
    Pincus T, Castrejón I.
    Bull Hosp Jt Dis (2013); 2013 Apr 14; 71 Suppl 1():S33-40. PubMed ID: 24219039
    [Abstract] [Full Text] [Related]

  • 11. Corticosteroids as disease modifying drugs in rheumatoid arthritis treatment.
    Yazici Y.
    Bull NYU Hosp Jt Dis; 2012 Apr 14; 70 Suppl 1():11-3. PubMed ID: 23259652
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The use of conventional disease-modifying anti-rheumatic drugs in established RA.
    Jurgens MS, Jacobs JW, Bijlsma JW.
    Best Pract Res Clin Rheumatol; 2011 Aug 14; 25(4):523-33. PubMed ID: 22137922
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis.
    Jacobs JW.
    Rheumatology (Oxford); 2012 Jun 14; 51 Suppl 4():iv3-8. PubMed ID: 22513146
    [Abstract] [Full Text] [Related]

  • 19. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct 14; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.